| Literature DB >> 24621454 |
Behrouz Gharesi-Fard1, Jaleh Zolghadri, Eskandar Kamali-Sarvestani.
Abstract
The placenta is a unique pregnancy-related tissue and plays a key role in occurrence of unexplained recurrent pregnancy loss (URPL). Abnormal placentation might play a key role in occurrence of URPL. Therefore, the purpose of this study was to compare the human placental proteome between URPL placentas and normal placental matched for gestational week. Total placental proteins were extracted, and the two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) technique was used for separation of the placental proteomes. Protein spots differentially expressed between URPL and normal placentas were selected and identified by the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI TOF/TOF) technique after being digested in the gel. Moreover, quantitative real-time PCR and Western blot techniques were used to confirm the differential expression mass results for some differentially expressed proteins. The results indicated that at least 19 protein spots were differentially expressed between URPL and normal placentas (P < 0.05), and twelve of them were successfully identified. While only two proteins were downregulated (calumenin and enolase 1), the remaining ten spots (actin gamma 1 propeptide, cathepsin D prepropeptide, heat shock protein gp96, tubulin beta, tubulin alpha 1, glutathione S-transferase, vitamin D binding protein, prohibitin, actin beta, apolipoprotein A-I) showed increased expression in URPL cases in comparison with normal placentas. Real-time PCR also confirmed the downregulation of calumenin and upregulation of prohibitin and apolipoprotein A-I at the mRNA levels. In conclusion, the results of the present study showed that alteration in the expression of proteins involved in proliferation and migration of endothelial cells as well as control of coagulation by these cells might play an important role in the pathogenesis of URPL.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24621454 PMCID: PMC4139499 DOI: 10.1262/jrd.2013-096
Source DB: PubMed Journal: J Reprod Dev ISSN: 0916-8818 Impact factor: 2.214
Fig. 1.Two representative silver-stained 2D-PAGE gels (15%, pH 4-7 linear). Differentially expressed spots are numbered. A: Normal gestational week-matched placenta proteome. B: URPL placenta proteome. C: Magnified view of differentially expressed spots.
Differentially expressed protein spots in URPL placentas as compared with normal gestational week-matched placentas, identified by the MALDI TOF/TOF/MASS technique
| Spot noa | Protein name | Mrb | pIb | Scorec | Accession no. |
| 10 | Actin, gamma 1 propeptide | 41837 | 5.44 | 192 | gi|4501887 |
| 14 | Cathepsin D prepropeptide | 45036.8 | 6.10 | 358 | gi|4503143 |
| 20 | Heat shock protein gp 96 precursor | 90309.1 | 4.73 | 151 | gi|15010550 |
| 35 | Actin, beta | 42077.9 | 5.29 | 72 | gi|16359158 |
| 70 | Tubulin, beta | 48135.1 | 4.70 | 239 | gi|57209813 |
| 78 | Apolipoprotein A-I | 28061.5 | 5.27 | 266 | gi|90108664 |
| 105 | Tubulin alpha 6 | 50547.7 | 4.96 | 373 | gi|14389309 |
| 106 | Enolase 1 | 47350.4 | 6.98 | 126 | gi|203282367 |
| 129 | Glutathione s-transferase | 23595.1 | 5.43 | 499 | gi|2204207 |
| 132 | Prohibitin | 29871 | 5.57 | 120 | gi|49456373 |
| 155 | Vitamin D binding protein | 54498.6 | 5.33 | 228 | gi|34785355 |
| 190 | Calumenin, isoform CRA-C | 38141.1 | 4.47 | 77 | gi|119604085 |
a Spot numbers are the same as the spot labels in Fig. 1. b Theoritical/mass (Dalton) or pI. c Protein scores of greater than 66 were considered statistically significant (P < 0.05).
Comparison of the mean percentage of intensity of differentially expressed spots between URPL and normal gestational week-matched placentas
| Spot no. | Protein name | Percentage intensity (Mean ± SD) | Expressiona | P-valueb | |
| URPL | Normal | ||||
| 10 | Actin, gamma 1 propeptide | 0.351 ± 0.012 | 0.194 ± 0.068 | + | 0.008 |
| 14 | Cathepsin D prepropeptide | 0.432 ± 0.029 | 0.331 ± 0.025 | + | 0.008 |
| 20 | Heat shock protein gp 96 precursor | 0.329 ± 0.015 | 0.203 ± 0.031 | + | 0.008 |
| 35 | Actin, beta | 0.316 ± 0.040 | 0.177 ± 0.045 | + | 0.016 |
| 70 | Tubulin, beta | 0.318 ± 0.039 | 0.224 ± 0.012 | + | 0.008 |
| 78 | Apolipoprotein A-I | 0.382 ± 0.041 | 0.277 ± 0.023 | + | 0.008 |
| 105 | Tubulin alpha 6 | 0.239 ± 0.020 | 0.150 ± 0.025 | + | 0.016 |
| 106 | Enolase 1 | 0.274 ± 0.033 | 0.393 ± 0.054 | – | 0.016 |
| 129 | Glutathione s-transferase | 0.174 ± 0.038 | 0.068 ± 0.033 | + | 0.008 |
| 132 | Prohibitin | 0.347 ± 0.024 | 0.260 ± 0.031 | + | 0.016 |
| 155 | Vitamin D binding protein | 0.310 ± 0.099 | 0.173 ± 0.012 | + | 0.032 |
| 190 | Calumenin, isoform CRA-C | 0.086 ± 0.009 | 0.151 ± 0.047 | – | 0.016 |
a Up- and downregulation of spots in URPL placentas as compared with normal placentas is indicated by + and –, respectively. b Exact P-value calculated by Mann-Whitney U test.
QRT-PCR analysis of Calumenin, ApoA-I and Prohibitin gene in URPL placentas as compared with normal placentas
| RNA expression (∆CT) | 2 -∆∆ct | % intensity at protein level | |||
| URPL (n=5) | Normal (n=5) | URPL (n=5) | Normal (n=5) | ||
| Mean ± SEM | Mean ± SEM | Mean ± SD | Mean ± SD | ||
| Calumenin | 17.53 ± 0.46 | 16.54 ± 1.05 | 0.51* | 0.086 ± 0.009 | 0.151 ± 0.047 |
| Apolipoprotein A-I | 18.02 ± 0.83 | 20.70 ± 0.35 | 6.10** | 0.382 ± 0.041 | 0.277 ± 0.023 |
| Prohibitin | 15.51 ± 0.61 | 16.22 ± 0.58 | 1.65*** | 0.347 ± 0.024 | 0.260 ± 0.031 |
The 2 -∆∆ct value is presented for the URPL/normal ratio. * P < 0.01; ** P < 0.001; *** P < 0.05.